Agomelatine increases BDNF serum levels in depressed patients in correlation with the improvement of depressive symptoms

International Journal of Neuropsychopharmacology

Volumn 19, Issue 5, 2016, Pages

  Martinotti, Giovanni ^a   Pettorruso, Mauro ^b   De Berardis, Domenico ^a   Varasano, Paola Annunziata ^c   Pressanti, Gabriella Lucidi ^c   De Remigis, Valeria ^c   Valchera, Alessandro ^d   Ricci, Valerio ^e   Di Nicola, Marco ^b   Janiri, Luigi ^b   Biggio, Giovanni ^f   Di Giannantonio, Massimo ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c 'G Mazzini' Hospital   (Italy)

^d Hermanas Hospitalarias   (Italy)

^e Pediatrician   (Italy)

^f UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Agomelatine; BDNF; Major depressive disorder

Indexed keywords

AGOMELATINE; AMINOTRANSFERASE; BRAIN DERIVED NEUROTROPHIC FACTOR; ACETAMIDE DERIVATIVE; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANHEDONIA; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEPRESSION; DIZZINESS; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MALE; MIDDLE AGED; NAUSEA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE; AFFECT; AGED; BLOOD; DRUG EFFECTS; ITALY; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; REMISSION; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; UPREGULATION;

ACETAMIDES; AFFECT; AGED; ANTIDEPRESSIVE AGENTS; BIOMARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; FEMALE; HUMANS; ITALY; LINEAR MODELS; MALE; MIDDLE AGED; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84979299503     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyw003     Document Type: Article

References (25)

1. Angelucci F, Ricci V, Gelfo F, Martinotti G, Brunetti M, Sepede G, Signorelli M, Aguglia E, Pettorruso M, Vellante F, Di Giannantonio M, Caltagirone C (2014) BDNF serum levels in subjects developing or not post-traumatic stress disorder after trauma exposure. Brain Cogn 84:118-122.
2. Bramham CR, Messaoudi E (2005) BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog Neurobiol 76:99-125.
3. Calabrese F, Molteni R, Gabriel C, Mocaer E, Racagni G, Riva MA (2011) Modulation of neuroplastic molecules in selected brain regions after chronic administration of the novel antidepressant agomelatine. Psychopharmacology (Berl) 215:267-275.
4. Castren E, Voikar V, Rantamaki T (2007) Role of neurotrophic factors in depression. Curr Opin Pharmacol 7:18-21.
5. Di Giannantonio M, Martinotti G (2012) Anhedonia and major depression: The role of agomelatine. European Neuropsychopharmacology 22 (3): S505-S510
6. Faraguna U, Vyazovskiy VV, Nelson AB, Tononi G, Cirelli C (2008) A causal role for brain-derived neurotrophic factor in the homeostatic regulation of sleep. J Neurosci 28:4088-4095.
7. Gumuslu E, Mutlu O, Sunnetci D, Ulak G, Celikyurt IK, Cine N, Akar F, Savli H, Erden F (2014) The antidepressant agomelatine improves memory deterioration and upregulates CREB and BDNF gene expression levels in unpredictable chronic mild stress (UCMS)-exposed mice. Drug Target Insights 8:11-21.
8. Kuczewski N, Porcher C, Gaiarsa JL (2010) Activity-dependent dendritic secretion of brain-derived neurotrophic factor modulates synaptic plasticity. Eur J Neurosci 32:1239-1244.
9. Ladurelle N, Gabriel C, Viggiano A, Mocaer E, Baulieu EE, Bianchi M (2012) Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC. Psychopharmacology (Berl) 221:493-509.
10. Li Y, Luikart BW, Birnbaum S, Chen J, Kwon CH, Kernie SG, Bassel-Duby R, Parada LF (2008) TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron 59:399-412.
11. Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000) Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20:9104-9110.
12. Martinotti G, Sepede G, Gambi F, Di Iorio G, De Berardis D, Di Nicola M, Onofrj M, Janiri L, Di Giannantonio M (2012) Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J Clin Psychopharmacol 32:487-491.
13. Millan MJ, Brocco M, Gobert A, Dekeyne A (2005) Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl) 177:448-458.
14. Molteni R, Calabrese F, Pisoni S, Gabriel C, Mocaer E, Racagni G, Riva MA (2010) Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration. World J Biol Psychiatry 11:148-153.
15. Olie JP, Kasper S (2007) Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10:661-673.
16. Païzanis E, Renoir T, Lelievre V, Saurini F, Melfort M, Gabriel C, Barden N, Mocaër E, Hamon M, Lanfumey L (2010) Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice. Int J Neuropsychopharmacol 13:759-774.
17. Papp M, Gruca P, Boyer P A, Mocaer E (2003) Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 28:694-703.
18. Racagni G, Riva MA, Molteni R, Musazzi L, Calabrese F, Popoli M, Tardito D (2011) Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. World J Biol Psychiatry 12:574-587.
19. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301:805-809.
20. Soumier A, Banasr M, Lortet S, Masmejean F, Bernard N, Kerkerian-Le-Goff L, Gabriel C, Millan MJ, Mocaer E, Daszuta A (2009) Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 34:2390-2403.
21. Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, Popoli M (2006) Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev 58:115-134.
22. Tardito D, Molteni R, Popoli M, Racagni G (2012) Synergistic mechanisms involved in the antidepressant effects of agomelatine. Eur Neuropsychopharmacol 22:S482-486.
23. Taylor D, Sparshatt A, Varma S, Olofinjana O (2014) Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 348:g1888.
24. Teixeira AL, Barbosa IG, Diniz BS, Kummer A (2010) Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function. Biomark Med 4:871-887.
25. Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, Shiraishi T, Shiina A, Hashimoto T, Kanahara N, Hasegawa T, Enohara M, Kimura A, Iyo M, Hashimoto K (2012) Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One 7:e42676.